Clinical Trials Browser

Recurrence × Genitourinary × 90 days × Clear all

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colonic Neoplasms, Esophageal Neoplasms, Kidney Neoplasms, Recurrence, Stomach Neoplasms

NCT07277413 2026-04-03

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Phase 1 Recruiting

260 enrolled

GastrointestinalGenitourinaryOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Mesothelioma, Neoplasm Metastasis, Recurrence

NCT07197580 2026-04-01

LUTEON

Phase 3 Recruiting

40 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

NCT07420517 2026-03-30

DutaBCa-1

Phase 2 Recruiting

95 enrolled

Genitourinary

Urinary Bladder Neoplasms, Recurrence

NCT02650401 2026-03-25

STARTRK-NG

Phase 1/2 Active not recruiting

69 enrolled 2 FDA

CNSEndocrineGenitourinaryHead & NeckSarcoma

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic

NCT05328505 2026-03-24

MIDAS-Prostate

Phase NA Recruiting

80 enrolled

Genitourinary

Adenocarcinoma, Prostatic Neoplasms, Recurrence

NCT05037279 2026-03-20

EVER

Phase 3 Recruiting

540 enrolled

Genitourinary

Urinary Bladder Neoplasms, Recurrence

NCT05283330 2026-03-20

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Phase 1 Recruiting

48 enrolled

BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Glioblastoma, Neoplasm Metastasis, Prostatic Neoplasms, Recurrence, Colorectal Neoplasms

NCT06126172 2026-03-20

Radiomics of Treatment-naive Prostate Cancer Patients on Multiparametric MRI for Risk Stratification and Treatment Outcomes Predictions

Phase NA Active not recruiting

125 enrolled

Genitourinary

Prostatic Neoplasms, Recurrence

NCT06551324 2026-03-04

MEVPRO-1

Phase 3 Recruiting

600 enrolled

Genitourinary

Prostatic Neoplasms, Recurrence

NCT06330064 2026-02-12

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

Phase 2 Recruiting

520 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Recurrence, Colorectal Neoplasms, Endometrial Neoplasms

NCT07391137 2026-02-09

CRUCIAL-R

Phase NA Active not recruiting

250 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Recurrence

Clinical Trials

JIVAN

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

LUTEON

DutaBCa-1

STARTRK-NG

MIDAS-Prostate

EVER

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Radiomics of Treatment-naive Prostate Cancer Patients on Multiparametric MRI for Risk Stratification and Treatment Outcomes Predictions

MEVPRO-1

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

CRUCIAL-R